Effect of omalizumab on peripheral blood eosinophilia in allergic asthma.

[1]  Calman Prussin,et al.  IgE, mast cells, basophils, and eosinophils. , 2003, The Journal of allergy and clinical immunology.

[2]  P. Gergen,et al.  Asthma cases attributable to atopy: results from the Third National Health and Nutrition Examination Survey. , 2007, The Journal of allergy and clinical immunology.

[3]  A. Chang,et al.  Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults. , 2007, The Cochrane database of systematic reviews.

[4]  H. Fox,et al.  Improvement in quality of life with omalizumab in patients with severe allergic asthma , 2006, Current medical research and opinion.

[5]  N. Suttorp,et al.  Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. , 2006, The Journal of allergy and clinical immunology.

[6]  J. Bousquet,et al.  The effect of treatment with omalizumab, an anti‐IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma , 2005, Allergy.

[7]  J. Bousquet,et al.  The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. , 2005, The Journal of allergy and clinical immunology.

[8]  J Bousquet,et al.  Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE , 2005, Allergy.

[9]  C. Lemière,et al.  Steroid naive eosinophilic asthma: anti-inflammatory effects of fluticasone and montelukast , 2005, Thorax.

[10]  E. Pizzichini,et al.  Failure of montelukast to reduce sputum eosinophilia in high-dose corticosteroid-dependent asthma , 2005, European Respiratory Journal.

[11]  D. Adamko,et al.  The rise of the phoenix: the expanding role of the eosinophil in health and disease , 2005, Allergy.

[12]  Stephen T Holgate,et al.  Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. , 2004, American journal of respiratory and critical care medicine.

[13]  A. Togias,et al.  Omalizumab-induced reductions in mast cell FcεRI expression and function , 2004 .

[14]  L. Boulet,et al.  Efficacy and tolerability of anti‐immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR , 2004, Allergy.

[15]  J. Bousquet,et al.  Efficacy and safety of a recombinant anti‐immunoglobulin E antibody (omalizumab) in severe allergic asthma , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[16]  T. Casale,et al.  Omalizumab rapidly decreases nasal allergic response and FcεRI on basophils , 2004 .

[17]  W. Lumry,et al.  Omalizumab is effective in the long-term control of severe allergic asthma. , 2003, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[18]  O. Noga,et al.  Immunological and Clinical Changes in Allergic Asthmatics following Treatment with Omalizumab , 2003, International Archives of Allergy and Immunology.

[19]  T. Casale,et al.  Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. , 2003, The Journal of allergy and clinical immunology.

[20]  E. Matsui,et al.  OMALIZUMAB PROVIDES LONG-TERM CONTROL IN PATIENTS WITH MODERATE-TO-SEVERE ALLERGIC ASTHMA , 2003 .

[21]  I. Pavord,et al.  Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial , 2002, The Lancet.

[22]  R. Townley,et al.  Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma , 2002, European Respiratory Journal.

[23]  T. Sandström,et al.  The effect of omalizumab on nasal allergic inflammation. , 2002, The Journal of allergy and clinical immunology.

[24]  W. Busse,et al.  Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. , 2001, The Journal of allergy and clinical immunology.

[25]  R. Townley,et al.  The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. , 2001, The European respiratory journal.

[26]  D. Dombrowicz,et al.  Human Eosinophils and Human High Affinity IgE Receptor Transgenic Mouse Eosinophils Express Low Levels of High Affinity IgE Receptor, but Release IL-10 upon Receptor Activation , 2001, The Journal of Immunology.

[27]  H. Lee,et al.  Serum Levels of Interleukins (IL)-4, IL-5, IL-13, and Interferon-γ in Acute Asthma , 2001 .

[28]  Y. Rhee,et al.  Serum levels of interleukins (IL)-4, IL-5, IL-13, and interferon-gamma in acute asthma. , 2001, The Journal of asthma : official journal of the Association for the Care of Asthma.

[29]  F. Levi-Schaffer,et al.  Blood eosinophils from atopic donors express messenger RNA for the α, β, and γ subunits of the high-affinity IgE receptor (FcϵRI) and intracellular, but not cell surface, α subunit protein , 2000 .

[30]  F. Levi-Schaffer,et al.  Blood eosinophils from atopic donors express messenger RNA for the alpha, beta, and gamma subunits of the high-affinity IgE receptor (Fc epsilon RI) and intracellular, but not cell surface, alpha subunit protein. , 2000, The Journal of allergy and clinical immunology.

[31]  R. Djukanović,et al.  The relationship between airways inflammation and asthma severity. , 2000, American journal of respiratory and critical care medicine.

[32]  I. Pavord,et al.  Non-eosinophilic cor ticosteroid unresponsive asthma , 1999, The Lancet.

[33]  M. Seminario,et al.  Intracellular Expression and Release of FcεRIα by Human Eosinophils , 1999, The Journal of Immunology.

[34]  H. Kita,et al.  Does IgE bind to and activate eosinophils from patients with allergy? , 1999, Journal of immunology.

[35]  A. Zwinderman,et al.  Effect of inhaled steroids on airway hyperresponsiveness, sputum eosinophils, and exhaled nitric oxide levels in patients with asthma , 1999, Thorax.

[36]  M. Wills-Karp.  Immunologic basis of antigen-induced airway hyperresponsiveness. , 1999, Annual review of immunology.

[37]  F. Hargreave,et al.  Anti-inflammatory effects of salmeterol compared with beclomethasone in eosinophilic mild exacerbations of asthma: a randomized, placebo controlled trial. , 1998, Canadian respiratory journal.

[38]  R. Dockhorn,et al.  Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. , 1997, The Journal of allergy and clinical immunology.

[39]  A. Togias,et al.  Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. , 1997, Journal of immunology.

[40]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .

[41]  Gary G. Koch,et al.  Categorical Data Analysis Using The SAS1 System , 1995 .

[42]  F. Kianifard,et al.  Poisson regression analysis in clinical research. , 1995, Journal of biopharmaceutical statistics.

[43]  F. Martinez,et al.  Association of asthma with serum IgE levels and skin-test reactivity to allergens. , 1989, The New England journal of medicine.